Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy
Hirotaka Kimura, Satoshi Eguchi, Junko Sasaki, Keiji Kuba, Hiroki Nakanishi, Shunsuke Takasuga, Masakazu Yamazaki, Akiteru Goto, Hiroyuki Watanabe, Hiroshi Itoh, Yumiko Imai, Akira Suzuki, Noboru Mizushima, Takehiko Sasaki
Hirotaka Kimura, Satoshi Eguchi, Junko Sasaki, Keiji Kuba, Hiroki Nakanishi, Shunsuke Takasuga, Masakazu Yamazaki, Akiteru Goto, Hiroyuki Watanabe, Hiroshi Itoh, Yumiko Imai, Akira Suzuki, Noboru Mizushima, Takehiko Sasaki
View: Text | PDF
Research Article Cardiology Cell biology

Vps34 regulates myofibril proteostasis to prevent hypertrophic cardiomyopathy

  • Text
  • PDF
Abstract

Hypertrophic cardiomyopathy (HCM) is a common heart disease with a prevalence of 1 in 500 in the general population. Several mutations in genes encoding cardiac proteins have been found in HCM patients, but these changes do not predict occurrence or prognosis and the molecular mechanisms underlying HCM remain largely elusive. Here we show that cardiac expression of vacuolar protein sorting 34 (Vps34) is reduced in a subset of HCM patients. In a mouse model, muscle-specific loss of Vps34 led to HCM-like manifestations and sudden death. Vps34-deficient hearts exhibited abnormal histopathologies, including myofibrillar disarray and aggregates containing αB-crystallin (CryAB). These features result from a block in the ESCRT-mediated proteolysis that normally degrades K63-polyubiquitinated CryAB. CryAB deposition was also found in myocardial specimens from a subset of HCM patients whose hearts showed decreased Vps34. Our results identify disruption of the previously unknown Vps34-CryAB axis as a potentially novel etiology of HCM.

Authors

Hirotaka Kimura, Satoshi Eguchi, Junko Sasaki, Keiji Kuba, Hiroki Nakanishi, Shunsuke Takasuga, Masakazu Yamazaki, Akiteru Goto, Hiroyuki Watanabe, Hiroshi Itoh, Yumiko Imai, Akira Suzuki, Noboru Mizushima, Takehiko Sasaki

×

Figure 4

Vps34 is required for autophagy-mediated protein degradation in cardiomyocytes.

Options: View larger image (or click on image) Download as PowerPoint
Vps34 is required for autophagy-mediated protein degradation in cardiomy...
(A) Immunoblot of heart lysates from Atg5fl/fl (cAtg5+/+), mckCre-Atg5fl/fl (cAtg5–/–), cVps34+/+, and cVps34–/– hearts to detect the indicated proteins. Results are representative of 3 trials. (B) Representative macroscopic views of hearts from cAtg5+/+ (n = 17) and cAtg5–/– (n = 18) mice at the indicated ages. P, postnatal day. (C) Heart/body weight ratios for cAtg5+/+ (n = 17) and cAtg5–/– (n = 18) mice. ns, not significant. (D) Representative M-mode echocardiograms in cAtg5+/+ and cAtg5–/– mice at P80. (E) Kaplan-Meier survival curves for cAtg5+/+ (n = 80) and cAtg5–/– (n = 88) littermate mice.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts